Autopsy report · NCT02303405

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

“Investigator decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 4 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Charles Drew University of Medicine and Science

Sponsor type

University, hospital or other

Conditions

Diabetes Mellitus Type 2 With Hyperglycemia

Interventions

Hydroxychloroquine; Pioglitazone

Participants

22

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.